Investigating Bone Cement With or Without Inossia™ Cement Softener for Vertebral Compression Fractures (SOFTBONE)

Inclusion Criteria: Informed consent obtained before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the patient, i.e. standard of care); Symptomatic osteoporotic vertebral compression fracture without prior or not responding to medical treatment within 6 months; Maximum of 1 level of vertebral compression fractures eligible for treatment localized at level Th5 to L5 and verified by MRI or bone scan; Height reduction of the affected vertebra(e) with an anterior wall compression of not exceeding 60% compared to the nearest normal vertebral body determined by X-ray; Have pain correlating to the fractured levels requiring regular analgesic intake and/or causing substantial disability of daily life; Pain score ≥ 40 mm measured by VAS correlating to at least one of the fracture levels (scale 0 - 100 mm) at the screening visit; Oswestry Disability Index > 20 (0 - 100 scale); SF-12PCS Index < 80 (0 - 100 scale); Patient with a communicative ability to understand the procedure and participate in the study and comply with the follow up program. Exclusion Criteria: Patients below 18 years; Any burst fracture; Unstable fractures defined by neurological deficit or interspinous process widening as evaluated by the Investigator, as well as kyphosis > 30°, translation > 4 mm; Established or suspected malignancy of the fractured vertebra. Hemangioma of the fractured vertebra; High energy trauma or clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis as suggested by progressive weakness; Have neurologic symptoms or deficits, or radiculopathy related to the fractured vertebrae; Patients with extremely high BMI, i.e. BMI ≥ 40; Previously treated with vertebroplasty or kyphoplasty; Patients with concomitant diseases which may be worsened by invasive treatment of the fracture such as e.g. severe cardiopulmonary dysfunction (including aortic aneurysm), as judged by the Investigator Irreversible coagulopathy or bleeding disorder. Note regarding reversible coagulopathies: Patients on Coumadin or other anticoagulants may participate. Investigators should follow routine practices for perioperative discontinuation and re- initiation of anticoagulants; Active systemic infection or local skin infection at the puncture site; Pregnancy or breast-feeding; Patients with known chemical dependency or drugs or with a medical history of drug abuse; Patients who are serving prison sentence; Have participated in another investigational study within 30 days prior to inclusion Pacemaker Previous or active radiotherapy affecting the spine